Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177-Lu-DOTAGA-IAB57
- Development stage
- Preclinical
- Lead developer
- ImaginAb
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177-Lu-DOTAGA-IAB57 is an investigational radiopharmaceutical therapy (RPT) developed by ImaginAb for the treatment of small cell lung cancer (SCLC). It consists of the IAB57 minibody—an 80 kDa antibody fragment—conjugated to the chelator DOTAGA and radiolabeled with the beta-emitting radioisotope Lutetium-177 (177-Lu). The minibody is engineered to specifically target Delta-like ligand 3 (DLL3), a Notch ligand that is highly overexpressed on the surface of SCLC cells but has minimal expression in normal tissues. The minibody scaffold is designed to provide optimal pharmacokinetics, offering deeper tumor penetration and faster systemic clearance than full-length antibodies while maintaining high target specificity. Preclinical studies presented at AACR 2024 demonstrated that 177-Lu-DOTAGA-IAB57 achieves significant tumor uptake and effectively reduces tumor size, leading to improved survival in SCLC models with a favorable dosimetry profile well below toxicity thresholds for critical organs.
- Other names
- 177Lu-DOTAGA-IAB57Lutetium (177Lu) DOTAGA-IAB57
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on 177-Lu-DOTAGA-IAB57.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177-Lu-DOTAGA-IAB57.